UNITED STATES
                  SECURITIES AND EXCHANGE COMMISSION
                        Washington, D.C.  20549

                               FORM 10-Q

(Mark One)

[x]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
     SECURITIES EXCHANGE ACT OF 1934

           For the quarterly period ended April 30, 2001

                                  OR

[ ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
     SECURITIES EXCHANGE ACT OF 1934

                     Commission file number 1-8696

                    COMPETITIVE TECHNOLOGIES, INC.
        (Exact name of registrant as specified in its charter)


     Delaware                                36-2664428
(State or other jurisdiction of         (I.R.S. Employer Identification No.)
incorporation or organization)


     1960 Bronson Road
     Fairfield, Connecticut                        06430
(Address of principal executive                 (Zip Code)
offices)

Registrant's telephone number, including area code: (203) 255-6044

                                   N/A
        Former name, former address and former fiscal year, if
                       changed since last report

Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15 (d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90
days.  Yes  X .          No   .

Common Stock outstanding as of June 1, 2001 - 6,124,537 shares

Exhibit Index on sequentially numbered page 21 of 22.

               Page 1 of 22 sequentially numbered pages


            COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES

                                 INDEX

PART I.  FINANCIAL INFORMATION                               Page No.

Item 1.  Condensed Financial Statements

A.   Financial Statements (Unaudited)

     Consolidated Balance Sheets at
       April 30, 2001 and July 31, 2000                         3

     Consolidated Statements of Operations for the
       three months ended April 30, 2001 and 2000               4

     Consolidated Statements of Operations for the
       nine months ended April 30, 2001 and 2000                5

     Consolidated Statement of Changes in
       Shareholders' Interest for the nine
       months ended April 30, 2001                              6

     Consolidated Statements of Cash Flows for the
       nine months ended April 30, 2001 and 2000                7

     Notes to Consolidated Financial Statements              8-12

Item 2.  Management's Discussion and Analysis of
           Financial Condition and Results of
           Operations                                       13-20

Item 3.  Quantitative and Qualitative Disclosures
           About Market Risk                                   20


PART II.  OTHER INFORMATION

Item 2.   Changes in Securities and Use of Proceeds            21

Item 6.   Exhibits and Reports on Form 8-K                     21

Signatures                                                     21


                      PART I.  FINANCIAL INFORMATION

              COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES
                        Consolidated Balance Sheets
                     April 30, 2001 and July 31, 2000
                                (Unaudited)

<TABLE>
<CAPTION>
                                                April 30,      July 31,
                                                  2001           2000
<S>                                          <C>             <C>
ASSETS

Current assets:
  Cash and cash equivalents                   $    741,100   $  1,716,375
  Short-term investments, at market              6,546,818      5,000,054
  Receivables, including $3,136 and
    $9,925 receivable from related parties
    in April and July, respectively                300,609      2,420,180
  Prepaid expenses and other current assets         77,389        149,483
    Total current assets                         7,665,916      9,286,092

Property and equipment, at cost, net                84,516        115,518
Advances to E.L. Specialists, Inc.                 427,273             --
Investments                                      1,525,685      1,525,685
Intangible assets acquired, principally
  licenses and patented technologies, net        1,062,666      1,166,670
Other non-current assets                           138,301             --
    TOTAL ASSETS                              $ 10,904,357   $ 12,093,965

LIABILITIES AND SHAREHOLDERS' INTEREST

Current liabilities:
  Accounts payable including $1,471
    payable to related parties in
    April                                     $    144,998   $     65,443
  Accrued liabilities                            2,186,194      2,100,410
    Total current liabilities                    2,331,192      2,165,853

Commitments and contingencies                           --             --

Shareholders' interest:
  5% preferred stock, $25 par value                 60,675         60,675
  Common stock, $.01 par value                      61,907         61,907
  Capital in excess of par value                27,022,524     27,053,542
  Treasury stock (common), at cost;
    69,498 shares in April                        (529,724)            --
  Accumulated deficit                          (18,042,217)   (17,248,012)
    Total shareholders' interest                 8,573,165      9,928,112

      TOTAL LIABILITIES AND SHAREHOLDERS'
        INTEREST                              $ 10,904,357   $ 12,093,965
</TABLE>

                          See accompanying notes


                PART I.  FINANCIAL INFORMATION (Continued)

              COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES
                   Consolidated Statements of Operations
            for the three months ended April 30, 2001 and 2000
                                (Unaudited)
<TABLE>
<CAPTION>

                                                  2001           2000
<S>                                           <C>            <C>
Revenues:
  Retained royalties                          $   416,562    $  553,402
  Retained royalty settlement                          --       736,375
  Revenues under service contracts,
    including $125 from related
    parties in 2000                                    --         9,233
                                                  416,562     1,299,010
Costs of technology management
  services (including patent enforcement
  costs of $791,880 and $83,506
  in 2001 and 2000, respectively)               1,306,196       496,093

General and administration expenses,
  of which $27,935 and $33,471 were
  paid to related parties in 2001
  and 2000, respectively                          287,354       346,752
                                                1,593,550       842,845
Operating income (loss)                        (1,176,988)      456,165

Interest income                                   107,909        97,922
Other income (expense), net                       (34,189)       26,013

Net income (loss)                              (1,103,268)      580,100

Other comprehensive income (loss):
  Net unrealized holding gains on
    available-for-sale securities                      --        10,998
  Reclassification adjustment for realized
    gains included in net income                       --       (25,748)

Comprehensive income (loss)                   $(1,103,268)   $  565,350

Net income (loss) per share:
  Basic and diluted                           $     (0.18)   $     0.09

Weighted average number of common
  shares outstanding:
    Basic                                       6,120,677     6,120,254
    Diluted                                     6,120,677     6,369,160
</TABLE>


                          See accompanying notes


                PART I.  FINANCIAL INFORMATION (Continued)

              COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES
                   Consolidated Statements of Operations
             for the nine months ended April 30, 2001 and 2000
                                (Unaudited)
<TABLE>
<CAPTION>

                                                  2001           2000
<S>                                           <C>            <C>
Revenues:
  Retained royalties                          $ 2,437,819    $ 2,116,361
  Retained royalty settlement                          --        736,375
  Revenues under service contracts
    including $9,925 from related
    parties in 2000                                 3,519        163,170
                                                2,441,338      3,015,906
Costs of technology management
  services (including patent enforcement
  costs of $1,157,757 and $189,471
  in 2001 and 2000, respectively)               2,390,775      1,572,413

General and administration expenses,
  of which $110,497 and $91,080 were
  paid to related parties in 2001
  and 2000, respectively                        1,132,912        927,565
                                                3,523,687      2,499,978
Operating income (loss)                        (1,082,349)       515,928

Interest income                                   339,554        261,597
Other income (expense), net                       (51,410)        90,234

Net income (loss)                                (794,205)       867,759

Other comprehensive income (loss):
  Net unrealized holding gains on
    available-for-sale securities                      --        105,863
  Reclassification adjustment for realized
    gains included in net income                       --        (90,238)

Comprehensive income (loss)                   $  (794,205)   $   883,384

Net income (loss) per share:
  Basic and diluted                           $     (0.13)   $      0.14

Weighted average number of common
  shares outstanding:
    Basic                                       6,161,868      6,043,586
    Diluted                                     6,161,868      6,145,690
</TABLE>

                          See accompanying notes


                   PART I.  FINANCIAL INFORMATION (Continued)

                       COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES
                 Consolidated Statement of Changes in Shareholders' Interest
                           for the nine months ended April 30, 2001
                                         (Unaudited)
<TABLE>
<CAPTION>

                                  Preferred Stock
                                 Shares                 Common Stock      Capital in
                               issued and             Shares              excess of        Treasury Stock        Accumulated
                               outstanding   Amount   issued    Amount    par value   Shares held      Amount      Deficit
<S>                               <C>       <C>      <C>        <C>      <C>             <C>         <C>        <C>
Balance - July 31, 2000           2,427     $60,675  6,190,785  $61,907  $27,053,542          --     $      --  $(17,248,012)
  Stock issued under 1996
    Directors' Stock
    Participation Plan. . . . .                                              (25,849)     11,540       100,849
  Stock issued to directors . .                                               (2,073)      2,898        25,620
  Stock issued to employee in
    lieu of cash compensation .                                               (3,096)      2,564        23,096
  Purchase of treasury stock. .                                                          (86,500)     (679,289)
  Net loss. . . . . . . . . . .                                                                                     (794,205)
Balance - April 30, 2001          2,427     $60,675  6,190,785  $61,907  $27,022,524     (69,498)    $(529,724) $(18,042,217)
</TABLE>

                             See accompanying notes


                PART I.  FINANCIAL INFORMATION (Continued)


              COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES
                   Consolidated Statements of Cash Flows
             for the nine months ended April 30, 2001 and 2000
                                (Unaudited)
<TABLE>
<CAPTION>
                                                    2001         2000
<S>                                             <C>          <C>
Cash flow from operating activities:
  Income (loss) from operations                 $  (794,205) $   867,759
    Noncash items included in income (loss)
      from operations:
      Retained royalty settlement paid with
        shares of NTRU common stock                      --     (736,375)
      Depreciation and amortization                 161,163      156,671
      Stock issued to employee in lieu
        of cash compensation                         20,000           --
      Stock issued to directors                      23,547           --
      Directors' stock and stock retirement
        plan accruals                               115,201      102,958
    Other                                                --      (34,238)
    Gain on sale of investment                           --      (90,503)
    Net changes in various operating accounts:
      Receivables                                 2,117,298      670,204
      Prepaid expenses and other current
        assets                                       72,094       67,763
      Accounts payable and accrued
        liabilities                                 125,138     (237,170)
Net cash flow from operating activities           1,840,236      767,069


Cash flow from investing activities:
  Purchases of property and equipment, net          (26,157)     (30,691)
  Purchases of other short-term investments, net (1,546,764)  (1,601,321)
  Investments in cost-method affiliates                  --     (687,108)
  Proceeds from sale of:
    Available-for-sale securities                        --      145,444
    Other short-term investments                         --          265
  Advances to E.L. Specialists, Inc.               (425,000)          --
  Increase in other non-current assets             (138,301)          --
Net cash flow from investing activities          (2,136,222)  (2,173,411)

Cash flow from financing activities:
  Proceeds from exercise of stock options                --    1,577,656
  Purchases of treasury stock                      (679,289)    (276,545)
Net cash flow from financing activities            (679,289)   1,301,111

Net decrease in cash and cash equivalents          (975,275)    (105,231)
Cash and cash equivalents, beginning
  of period                                       1,716,375      185,838
Cash and cash equivalents, end of period        $   741,100  $    80,607
</TABLE>

                          See accompanying notes


             PART I.  FINANCIAL INFORMATION (Continued)

           COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES

             Notes to Consolidated Financial Statements
                             (Unaudited)


1.   Interim Financial Statements

     Interim financial information presented in the accompanying
financial statements and notes hereto is unaudited.

     The year-end balance sheet data was derived from audited
financial statements but does not include all disclosures required
by generally accepted accounting principles.

     In the opinion of management, all adjustments necessary to
present the financial statements fairly in conformity with generally
accepted accounting principles, consisting only of normal recurring
adjustments, have been made.

     The interim financial statements and notes thereto as well as
the accompanying Management's Discussion and Analysis of Financial
Condition and Results of Operations should be read in conjunction
with the Company's Annual Report on Form 10-K for the year ended
July 31, 2000.

2.   Net Income (Loss) Per Share

     The following table sets forth the computations of basic and
diluted net income (loss) per share.

<TABLE>
<CAPTION>
                                     Nine months                 Quarter
                                   ended April 30,           ended April 30,
                                  2001         2000         2001         2000
<S>                          <C>          <C>          <C>           <C>
Net income (loss) applicable
  to common stock:
  Basic and diluted          $ (794,205)  $   867,759  $(1,103,268)  $  580,100

Weighted average number
  of common shares
  outstanding                 6,161,868     6,043,586    6,120,677    6,120,254
Effect of dilutive
  securities:
  Stock options                      --       100,011           --      242,534
  Stock warrants                     --         2,093           --        6,372
Weighted average number
  of common shares
  outstanding and dilutive
  securities                  6,161,868     6,145,690    6,120,677    6,369,160

Net income (loss) per
  share of common stock:
  Basic and diluted          $    (0.13)  $      0.14  $     (0.18)  $     0.09
</TABLE>

    At April 30, 2001, options and warrants to purchase 683,517
shares of common stock were outstanding but were not included in the
computation of earnings per share because they were anti-dilutive.
At April 30, 2000, all outstanding options and warrants were
dilutive.

3.  Receivables

    Receivables were:
                                    April 30,           July 31,
                                      2001                2000

     Royalties                     $  247,209         $2,347,176
     Other                             53,400             73,004
                                   $  300,609         $2,420,180

4.   Advances to E.L. Specialists, Inc.

     Between January and April 30, 2001, CTT advanced $425,000 to
E.L. Specialists, Inc. in exchange for a promissory note.  The
promissory note, as renewed and extended, provides for advances up
to $600,000 with simple interest at 7% per year and principal due on
or before July 12, 2001.  As of June 13, 2001, the Company had
advanced the total $600,000 under this note.  Under a related note
purchase agreement, CTT agreed to exchange the entire amount due on
the note for shares of Series A Preferred Stock and related
securities of E.L. Specialists, Inc. if and when E.L. Specialists,
Inc. completes its proposed financing.  E.L. Specialists, Inc. is a
Texas corporation established to develop and commercialize a
flexible printed electroluminescent lighting technology.  We provide
certain technology evaluation, marketing and licensing services for
E.L. Specialists, Inc. under our agreement with them.

5.   Accrued Liabilities

     Accrued liabilities were:

                                    April 30,           July 31,
                                      2001                2000

     Royalties payable             $1,065,388         $1,780,988
     Accrued professional
       fees payable                   862,037             95,510
     Accrued compensation             113,669            147,766
     Deferred revenues                100,000             10,521
     Other                             45,100             65,625
                                   $2,186,194         $2,100,410

6.   Contingencies

Litigation

Fujitsu

     In December 2000, CTT filed a complaint with the United States
International Trade Commission (ITC) on behalf of CTT and the
University of Illinois against Fujitsu Limited of Tokyo, Japan,
Fujitsu Hitachi Plasma Display Limited, Japan, et al. (Fujitsu)
under Section 337 of the Tariff Act of 1930, as amended.  CTT
requested that the ITC stop Fujitsu and/or its subsidiaries from
unlawfully importing plasma display panels (PDPs) into the United
States on the basis that the panels infringe U.S. Patent Numbers
4,866,349 and 5,081,400 held by CTT's client, the University of
Illinois.  The two patents emanate from the scientific discoveries
of Larry F. Weber, Kevin W. Warren and Mark B. Wood.  Their
inventions provide for energy recovery used in PDPs and plasma
display flat-screen televisions.

     The ITC has power to issue orders directing U.S. Customs
officials to stop future importation of Fujitsu PDPs and plasma
display products that infringe the two named patents.  In January
2001 the ITC voted to investigate CTT's complaint and referred the
investigation to an ITC administrative law judge.  This judge is
scheduled to hear the evidence beginning in August 2001 and make an
initial determination as to any violation in late November 2001.
This initial determination is subject to review by the full
Commission.  The ITC's target date to complete this investigation is
late February 2002.

     Coincident with filing its ITC complaint, CTT and the
University of Illinois also filed a complaint against Fujitsu in the
United States District Court for the Central District of Illinois
seeking damages for past infringements and an injunction against
future sales of PDPs that infringe these patents.

     CTT is unable to estimate the related legal expenses it may
incur in connection with these proceedings.

LabCorp

     On May 4, 1999, Metabolite Laboratories, Inc. (MLI) and CTT
(collectively plaintiffs) filed a complaint and jury demand against
Laboratory Corporation of America Holdings d/b/a LabCorp (LabCorp)
in the United States District Court for the District of Colorado.
The complaint alleges, among other things, that LabCorp owes
plaintiffs royalties for homocysteine assays performed beginning in
the summer of 1998 using methods and materials falling within the
claims of a patent owned by CTT.  CTT licensed the patent non-
exclusively to MLI and MLI sublicensed it to LabCorp.  Plaintiffs
claim LabCorp's actions constitute breach of contract and patent
infringement.  The claim seeks an injunction ordering LabCorp to
perform all its obligations under its agreement, to cure past
breaches, to provide an accounting of wrongfully withheld royalties
and to refrain from infringing the patent.  Plaintiffs also seek
unspecified money and exemplary damages and attorneys' fees, among
other things.  LabCorp has filed an answer and counterclaims
alleging noninfringement, patent invalidity and patent misuse.
Discovery has been completed.  Trial is scheduled to begin in
November 2001.  CTT is unable to estimate the related legal expenses
it may incur in this suit and has recorded no revenue for these
withheld royalties.

MaternaTM

     The University of Colorado Foundation, Inc., the University of
Colorado, the Board of Regents of the University of Colorado, Robert
H. Allen and Paul A. Seligman, plaintiffs, previously filed a
lawsuit against American Cyanamid Company, defendant, in the United
States District Court for the District of Colorado.  This case
involved a patent for an improved formulation of MaternaTM, a
prenatal vitamin compound sold by defendant.  While the Company was
not and is not a party to this case, the Company had a contract with
the University of Colorado to license University of Colorado
inventions to third parties.  As a result of this contract, the
Company is entitled to share approximately 18% of damages awarded to
the University of Colorado, if any, after deducting the expenses of
this suit.  On November 19, 1999, the United States Court of Appeals
for the Federal Circuit vacated a July 7, 1997, judgment by the
District Court in favor of plaintiffs for approximately $44 million
and remanded the case to the District Court for further proceedings.
On July 7, 2000, the District Court concluded that Robert H. Allen
and Paul A. Seligman were the sole inventors of the reformulation of
MaternaTM that was the subject of the patent and that defendant is
liable to them and the other plaintiffs on their claims for fraud
and unjust enrichment.  The District Court also reopened all issues
of damages and ordered a retrial to determine the nature and amount
of damages to be paid by defendant.  The damages retrial was heard
in March 2001 and the parties await the judge's decision.  The
Company cannot predict the amount of its share of the judgment, if
any, which may ultimately be awarded.  The Company has recorded no
potential judgment proceeds in its financial statements to date.
The Company has agreed to pay its proportionate share of out-of-
pocket costs and expenses (excluding attorneys' fees) incurred since
August 1, 2000 through the conclusion of this suit.  This agreement
provides for the Company's reimbursement from potential judgment
proceeds, if any, for costs and expenses it may pay.  The Company is
unable to estimate the costs and expenses it may incur in this suit
in the future.  The Company records these expenses as they are
incurred and will record their reimbursement, if any, when the
judgment is finally determined.

Optical Associates, Limited Partnership (OALP)

     In 1989 University Optical Products Co. (UOP), a majority-owned
subsidiary of CTT that had developed a computer-based system to
manufacture specialty contact lenses, intraocular lenses and other
precision optical products, sold substantially all its assets to
Unilens Corp. USA (Unilens).  The proceeds of the sale included an
installment obligation for $5,500,000 payable at a minimum of
$250,000 per year beginning in January 1992.  Due to the uncertainty
of the timing and amount of future cash flows, income on the
installment obligation is recorded net of related expenses as the
payments are received.  Cash received in excess of the fair value
assigned to the original obligation is recorded as other income from
continuing operations.  As cash proceeds are received, CTT records a
4% commission expense payable to its joint venture partner, Optical
Associates, Limited Partnership (OALP).  Unilens made no payments in
fiscal 2001 or 2000.  Through April 30, 2001, the Company had
received aggregate cash proceeds of approximately $1,011,000 from
the January 1989 sale of UOP's assets to Unilens.

     In November 1991, a lawsuit was filed in Connecticut against
CTT, its wholly-owned subsidiary, Genetic Technology Management,
Inc. (GTM), its majority-owned subsidiary, UOP, and one current and
several former directors on behalf of the 59 limited partners of
OALP.  The complaint alleges, among other things, that the January
1989 sale of UOP's assets to Unilens violated the partnership
agreement and that OALP is entitled to the full proceeds of the sale
to Unilens.  The complaint claims, among other things, money damages
and treble and punitive damages in an unspecified amount and
attorneys' fees.  The Company believes that the asserted claims are
without merit and intends to continue to defend vigorously the
action instituted by plaintiffs.  An attorney referee has heard the
case.  In November 2000, the Company made a motion to dismiss the
case and the attorney referee instructed both parties to prepare
their final briefs.  Both parties have prepared their briefs and
rebuttals.  The Company anticipates the attorney referee's decision
by July 31, 2001.  CTT recognized other expenses of $51,410 and $269
in the three quarters of fiscal 2001 and 2000, respectively, for
legal expenses related to this suit.

7.   Subsequent Event

     In May 2001, CTT advanced $100,000 to Micro-ASI, Inc. under a
secured bridge promissory note.  The promissory note provides for
interest compounded daily at a rate of 14% per year.  Principal and
interest are due on or before June 22, 2001.  Micro-ASI's
obligations under this and other bridge notes are secured by a
pledge of substantially all of its and its subsidiaries' assets
under a related bridge security agreement.  CTT owns approximately
2% of Micro-ASI's outstanding share capital and accounts for its
$500,000 investment under the cost method.  In June 2001, an
investor in Micro-ASI, Inc. demanded redemption of its 4,500,000
shares of preferred stock of Micro-ASI, Inc. at $1 per share plus
cumulative accrued and unpaid dividends on those shares.  Micro-ASI
is a Texas corporation which plans to provide semiconductor
packaging customers a one-stop-shop for flip-chip technology,
including design, prototype development, and volume manufacturing of
modules and boards.

             PART I.  FINANCIAL INFORMATION (Continued)


Item 2.  Management's Discussion and Analysis of Financial Condition
and Results of Operations


Financial Condition and Liquidity

     At April 30, 2001, cash and cash equivalents of $741,100 were
$975,275 lower than cash and cash equivalents of $1,716,375 at July
31, 2000.  Operating activities provided $1,840,236, investing
activities used $2,136,222 and financing activities used $679,289.

     In addition, Competitive Technologies, Inc. (CTT) and its
majority-owned subsidiaries (the Company or we) held $6,546,818 in
short-term investments at April 30, 2001.  These investments are
available for our future operating, investing and financing
activities.

     The Company's net loss for the nine months ended April 30,
2001, included non-cash charges of approximately $161,000 for
depreciation and amortization and approximately $159,000 for
employee and directors' stock compensation and stock retirement plan
accruals.

     In general, changes in various operating accounts result from
changes in the timing and amounts of cash flows before and after the
end of the period.  The most substantial changes in operating
accounts were the $2,099,967 decrease in royalties receivable and
the $715,600 decrease in royalties payable.  These changes in
royalties receivable and payable reflect our normal cycle of royalty
collections and payments.

     In the third quarter of fiscal 2001, we granted a license to a
technology for one use and granted an option to license the same
technology for another use.  We made both agreements with one
company.  The company paid both a license issue fee and an option
fee, but our agreements do not provide for another license issue fee
if or when the company exercises the option.  We treated these
agreements as a multiple element arrangement and deferred the
$100,000 license issue and option fee revenue.  We expect to
recognize this revenue when the company exercises the option and
executes the second license or when the option expires.

     During the nine months ended April 30, 2001, we purchased
$1,546,764 of short-term investments, all of which are highly liquid
investments.

     Between January and April 30, 2001, we advanced $425,000 to
E.L. Specialists, Inc. in exchange for a promissory note.  The
promissory note, as renewed and extended, provides for advances up
to $600,000 with simple interest at 7% per year and principal due on
or before July 12, 2001.  As of June 13, 2001, we had advanced the
total $600,000 under this note.  Under a related note purchase
agreement, we agreed to exchange the entire amount due on the note
for shares of Series A Preferred Stock and related securities of
E.L. Specialists, Inc. if and when E.L. Specialists, Inc. completes
its proposed financing.  E.L. Specialists, Inc. is a Texas
corporation established to develop and commercialize a flexible
printed electroluminescent lighting technology.  We provide certain
technology evaluation, marketing and licensing services for E.L.
Specialists, Inc. under our agreement with them.

     In October 1998, the Board of Directors authorized CTT to
repurchase up to 250,000 shares of its common stock.  CTT may
repurchase shares on the open market or in privately negotiated
transactions at times and in amounts determined by management based
on its evaluation of market and economic conditions.  CTT
repurchased 86,500 shares of its common stock for $679,289 in cash
in the nine months ended April 30, 2001.  From October 1998 through
April 30, 2001, CTT has repurchased 161,300 shares of its common
stock for a total of $1,065,213.  From October 1998 through April
30, 2001, CTT had reissued 91,802 of those repurchased shares rather
than issue new shares to satisfy an employee's moving allowance,
employees' exercises of stock options, grants of stock to directors
and contributions of shares of CTT's common stock under other
employee and director plans.

     In May 2001, we advanced $100,000 to Micro-ASI, Inc. under a
secured bridge promissory note.  The promissory note provides for
interest compounded daily at a rate of 14% per year.  Principal and
interest are due on or before June 22, 2001.  Micro-ASI's
obligations under this and other bridge notes are secured by a
pledge of substantially all of its and its subsidiaries' assets
under a related bridge security agreement.  CTT owns approximately
2% of Micro-ASI's outstanding share capital and accounts for its
$500,000 investment in Micro-ASI under the cost method.  In June
2001, an investor in Micro-ASI, Inc. demanded redemption of its
4,500,000 shares of preferred stock of Micro-ASI, Inc. at $1 per
share plus cumulative accrued and unpaid dividends on those shares.
Micro-ASI is a Texas corporation which plans to provide
semiconductor packaging customers a one-stop-shop for flip-chip
technology, including design, prototype development, and volume
manufacturing of modules and boards.  Micro-ASI reported net current
liabilities of $4.4 million at December 31, 2000, a $10.7 million
net loss for the twelve months ended December 31, 2000, and a $4
million net loss for the three months ended March 31, 2001.  Micro-
ASI also reported $6.5 million of debt maturing in 2001 and borrowed
an additional $1.4 million (including the $100,000 from CTT) between
December 31, 2000 and May 15, 2001.  Micro-ASI's management seeks to
complete a substantial private placement during 2001 to provide it
sufficient capital resources to achieve its operating plan.  Should
Micro-ASI not raise this additional capital, its operations will be
materially adversely affected and our investment in and advances to
Micro-ASI would be substantially impaired.

     At April 30, 2001, the Company had no outstanding commitments
for capital expenditures other than those discussed above.

     The Company carries liability insurance, directors' and
officers' liability insurance and casualty insurance for owned or
leased tangible assets.  It does not carry key person life
insurance.  There are no legal restrictions on payments of dividends
by CTT.

     We continue to pursue additional technology commercialization
opportunities.  If and when such opportunities are consummated, we
may commit capital resources to them.

     We do not believe inflation had a significant impact on our
operations during fiscal 2001 or 2000 or that it will have a
significant impact on our operations during the next twelve-month
operating period.

     The Company is involved in four pending litigation matters.
Full descriptions of them are reported in Note 6 to the accompanying
Consolidated Financial Statements.  During the nine months ended
April 30, 2001, the Company incurred a total of approximately
$1,158,000 of unreimbursed patent litigation expenses in the three
patent related suits.  The Company expects to continue to incur
substantial unreimbursed patent litigation expenses in its fourth
fiscal quarter and its next fiscal year as it pursues enforcement of
its patent rights in these three suits.

     At April 30, 2001, we had cash and cash equivalents of
$741,100, short-term investments of $6,546,818, royalties receivable
of $247,209 and royalties payable of $1,065,388.  Total assets were
$10,904,357, total liabilities were $2,331,192 and total
shareholders' interest was $8,573,165.

     Based on our current expectations, we anticipate that currently
available funds will be sufficient to finance our cash needs for the
foreseeable future for our current operating activities, including
patent enforcement litigation.  However, expansion of our business
is subject to many factors outside our control or that we cannot
currently anticipate, including without limitation business
opportunities that may arise in the future.  Accordingly, there can
be no assurance that our current expectations regarding the
sufficiency of currently available funds will prove to be accurate.

Results of Operations - Three Months Ended April 30, 2001 (Third
Quarter of Fiscal 2001) vs. Three Months Ended April 30, 2000 (Third
Quarter of Fiscal 2000)

     Total revenues for the third quarter of fiscal 2001 were
$416,562, $882,448 (68%) lower than for the third quarter of fiscal
2000.  Retained royalties for the third quarter of fiscal 2001 were
$416,562, $136,840 (25%) lower than for the third quarter of fiscal
2000.  For the third quarter of fiscal 2000, we recorded retained
royalty settlement revenues of $736,375 for the estimated fair value
of the royalty participation we exchanged for 2,945,500 shares of
NTRU common stock valued at $0.25 per share.  We had no similar
royalty settlement in the third quarter of fiscal 2001.

     Retained royalties for the third quarter of fiscal 2000
included approximately $168,000 from a homocysteine licensee's
increase in its previously estimated royalties for the period from
1995 through 1999.  Retained royalty revenue fluctuations for the
third quarter of fiscal 2001 also included new license issue fees
and changes in the timing of royalties reported by licensees.
Historically, the Company's royalty revenues in its second and
fourth fiscal quarters have been higher than in its first and third
fiscal quarters because of license agreements with semi-annual
reporting periods.

     In the third quarter of fiscal 2001, we recorded approximately
$500 in retained royalty revenues on our endoscopic ligator.  An
arbitrator ruled that claims in our current patent were invalid.
Since the arbitrator's ruling, licensees of this technology have
withheld royalties.  Our retained royalties from the endoscopic
ligator were approximately $138,000 and $247,000 for the fiscal
years ended July 31, 2000 and 1999, respectively.  We amended our
claims, filed for reexamination of our patent and received the
reexamination certificate.  We believe we are entitled to all
withheld and future royalties, but we cannot predict when, if ever,
licensees will resume remitting royalties for this technology.

     Revenues under service contracts for the third quarter of
fiscal 2001 were $9,233 lower than for the third quarter of fiscal
2000.  We are not actively seeking additional fee-for-service
contracts, although we may agree to them in the future in certain
circumstances.  Many of our service contracts are one-time
arrangements unique to a particular client at a particular time.

     Total operating expenses for the third quarter of fiscal 2001
were $1,593,550.  This was $750,705 (89%) higher than for the third
quarter of fiscal 2000.  A substantial portion of this reflects
increased expenses related to patenting and licensing incurred
principally to enforce our patent rights.  Other increases included
recruiting fees in connection with hiring additional technology
commercialization professionals in February and March 2001.  We
employed approximately 11 people full-time in the third quarter of
fiscal 2001 compared with 12 in the third quarter of fiscal 2000.
We supplement our current staff with consultants' services in
certain matters.

     Costs of technology management services for the third quarter
of fiscal 2001 were $1,306,196, $810,103 (163%) higher than for the
third quarter of fiscal 2000, as more fully discussed below.

     Costs related to licensing and retained royalties were
approximately $750,000 higher in the third quarter of fiscal 2001
than in the third quarter of fiscal 2000.  Approximately $711,000 of
this increase related to increased patent litigation expenses for
the three cases in which the Company and its clients have sued to
enforce their patent rights.  The International Trade Commission
(ITC) judge is scheduled to hear the Fujitsu case starting in August
2001.  The judge heard the damages retrial of the MaternaTM prenatal
vitamin case in March 2001 and the parties await his decision.  The
Company has agreed to pay its proportionate share of out-of-pocket
expenses (excluding attorneys' fees) from August 1, 2000 in the
MaternaTM prenatal vitamin litigation (See Note 6 to the accompanying
Consolidated Financial Statements).  The trial in the LabCorp suit
is scheduled to begin in November 2001.  The Company expects to
continue to incur substantial unreimbursed patent litigation
expenses in its fourth fiscal quarter and its next fiscal year as it
pursues enforcement of its patent rights in these three suits.
Personnel costs associated with patenting and licensing also
increased.  Costs related to licensing and retained royalties
include personnel costs (including benefits and overheads)
associated with patenting and licensing, patent litigation and
enforcement expenses (net of reimbursements), and domestic and
foreign patent prosecution and maintenance expenses (net of
reimbursements).

     Costs related to service contracts were approximately $29,000
lower for the third quarter of fiscal 2001 than for the third
quarter of fiscal 2000.  This decrease results from our move away
from fee-for-service contracts to a focus on licensing and enforcing
intellectual property rights and investing in ventures where, in
addition to making cash investments, we can provide intellectual
property and technology commercialization expertise.

     Costs associated with new client development for the third
quarter of fiscal 2001 (principally personnel costs, including
benefits and overheads) were approximately $89,000 higher than for
the third quarter of fiscal 2000.  With the addition of two
technology commercialization professionals to our staff, we expect
to continue to increase our efforts focused on new client
development.

     General and administration expenses in the third quarter of
fiscal 2001 were $59,398 (17%) lower than in the third quarter of
fiscal 2000.  Recruiting fees in connection with hiring additional
technology commercialization professionals in February and March
2001 partially offset lower personnel and related expenses.

     The $882,448 decrease in operating revenues and the $750,705
increase in operating expenses resulted in an operating loss of
$1,176,998 for the third quarter of fiscal 2001.

     Interest income of $107,909 in the third quarter of fiscal 2001
was $9,987 (10%) higher than in the third quarter of fiscal 2000.
The Company's average invested balance was approximately 18% higher
and its weighted average interest rate was approximately 0.38% per
annum lower than for the third quarter of fiscal 2000.

     During the third quarter of fiscal 2000, the Company sold
available-for-sale securities and realized gains of $25,748, which
were included in other income.  There were no such sales in the
third quarter of fiscal 2001.

     Other expenses in the third quarter of fiscal 2001 were legal
expenses incurred in connection with a suit brought against CTT,
some of its subsidiaries and directors (See Note 6 to the
accompanying Consolidated Financial Statements).

     The Company has approximately $12,869,000 of Federal net
operating loss carryforwards of which approximately $4,343,000 and
$4,371,000 expire in fiscal 2001 and 2002, respectively.  The
Company's ability to derive future tax benefits from its net
deferred tax assets is uncertain and therefore the valuation
allowance completely offsets them.

     In December 1999, the staff of the Securities and Exchange
Commission issued Staff Accounting Bulletin No. 101, "Revenue
Recognition in Financial Statements" (SAB 101).  SAB 101 as amended
to date (a) summarizes certain of the staff's views in applying
generally accepted accounting principles to revenue recognition in
financial statements and (b) requires companies to analyze their
revenue recognition policies for compliance with generally accepted
accounting principles summarized in SAB 101 no later than the fourth
quarter of fiscal years beginning after December 15, 1999.  The
Company is currently assessing the impact of SAB 101 on its
financial statements.

Results of Operations - Nine Months Ended April 30, 2001 (Three
Quarters of Fiscal 2001) vs. Nine Months Ended April 30, 2000 (Three
Quarters of Fiscal 2000)

     Total revenues for the three quarters of fiscal 2001 were
$2,441,338, $574,568 (19%) lower than for the three quarters of
fiscal 2000.  For the three quarters of fiscal 2001, retained
royalties were $2,437,819, $321,458 (15%) higher than for the three
quarters of fiscal 2000.

     Retained royalties from the gallium arsenide semiconductor
inventions, which include laser diode applications, were
approximately $1,295,000 in the three quarters of fiscal 2001, an
increase of approximately $684,000 or 112%.  This increase resulted
principally from increased sales of licensed products.  We cannot
predict whether our licensees' sales of licensed products will
continue to grow at this rate.  We recognize a substantial portion
of these royalties in our second and fourth fiscal quarters when
certain of these licensees report their semi-annual royalties.

     Reductions in retained royalties from other technologies
partially offset this increase.  These reductions related to
expiration of certain Vitamin B12 assay patents, licensees' withheld
royalties on our endoscopic ligator (discussed below), a
homocysteine licensee's increase in its previously estimated
royalties for the period from 1995 through 1999 reported in the
third quarter of fiscal 2000, changes in the timing of royalties
reported by licensees and in licensees' sales of licensed products.
New option and license issue fees and a licensee's correction of
previously reported royalties partially offset these reductions.

     In the three quarters of fiscal 2001, retained royalty revenues
on our endoscopic ligator were less than $1,500 and approximately
$136,000 lower than in the three quarters of fiscal 2000.  As
discussed more completely above, our patent reissued during the
third quarter of fiscal 2001 and we believe we are entitled to all
withheld and future royalties.  However, we cannot predict when, if
ever, licensees will resume remitting royalties for this technology.

     For the three quarters of fiscal 2000, we recorded retained
royalty settlement revenues of $736,375 for the estimated fair value
of the royalty participation we exchanged for 2,945,500 shares of
NTRU common stock valued at $0.25 per share.  We had no similar
royalty settlement in the three quarters of fiscal 2001.

     Revenues under service contracts for the three quarters of
fiscal 2001 were $159,651 lower than for the three quarters of
fiscal 2000.  We are not actively seeking additional fee-for-service
contracts, although we may agree to them in the future in certain
circumstances.  In the three quarters of fiscal 2000, we earned
revenues from two non-recurring service contracts, one for a
government agency and one for a domestic start-up corporation.  Many
of our service contracts are one-time arrangements unique to a
particular client at a particular time.

     Total operating expenses for the three quarters of fiscal 2001
were $3,523,687.  This was $1,023,709 (41%) higher than for the
three quarters of fiscal 2000.  A substantial portion of this
reflects increased expenses related to patenting and licensing
incurred principally to enforce our patent rights.  Other increases
included recruiting fees in connection with hiring additional
technology commercialization professionals in February and March
2001, consultants' fees and expenses, and directors' stock
compensation expense which more than offset reductions in personnel
and related expenses.  We employed approximately 11 people full-time
in the three quarters of fiscal 2001 compared with 13 in the three
quarters of fiscal 2000.  We supplement our current staff with
consultants' services in certain matters.

     Costs of technology management services for the three quarters
of fiscal 2001 were $2,390,775, $818,362 (52%) higher than for the
three quarters of fiscal 2000, as more fully discussed below.

     Costs related to licensing and retained royalties were
approximately $1,062,000 higher in the three quarters of fiscal 2001
than in the three quarters of fiscal 2000.  Approximately $962,000
of this increase relates to increased patent litigation expenses
(net of reimbursements) for the three cases in which the Company and
its clients have sued to enforce their patent rights.  The
International Trade Commission (ITC) judge is scheduled to hear the
Fujitsu case starting in August 2001.  The judge heard the damages
portion of the MaternaTM prenatal vitamin case in March 2001 and the
parties await his decision.  The Company has agreed to pay its
proportionate share of out-of-pocket expenses (excluding attorneys'
fees) from August 1, 2000 in the MaternaTM prenatal vitamin
litigation (See Note 6 to the accompanying Consolidated Financial
Statements).  The trial in the LabCorp suit is scheduled to begin in
November 2001.  The Company expects to continue to incur substantial
unreimbursed patent litigation expenses in its fourth fiscal quarter
and its next fiscal year as it pursues enforcement of its patent
rights in these three suits.  Personnel costs associated with
patenting and licensing also increased.  Costs related to licensing
and retained royalties include personnel costs (including benefits
and overheads) associated with patenting and licensing, patent
litigation and enforcement expenses (net of reimbursements), and
domestic and foreign patent prosecution and maintenance expenses.

     Costs related to service contracts were approximately $145,000
lower for the three quarters of fiscal 2001 than for the three
quarters of fiscal 2000.  This decrease results from our move away
from fee-for-service contracts to a focus on licensing and enforcing
intellectual property rights and investing in ventures where, in
addition to making cash investments, we can provide intellectual
property and technology commercialization expertise.

     Costs associated with new client development for the three
quarters of fiscal 2001 (principally personnel costs, including
benefits and overheads) were approximately $99,000 higher than for
the three quarters of fiscal 2000.  With the addition of two
technology commercialization professionals to our staff, we expect
to continue to increase our efforts focused on new client
development.

     General and administration expenses in the three quarters of
fiscal 2001 were $205,347 (22%) higher than in the three quarters of
fiscal 2000.  Increases included recruiting fees in connection with
hiring additional technology commercialization professionals in
February and March 2001, consultants' fees and expenses, and
directors' stock compensation expense.  These increases more than
offset reductions in personnel and related expenses.

     The $574,568 decrease in operating revenues and the $1,023,709
increase in operating expenses resulted in an operating loss of
$1,082,349 for the three quarters of fiscal 2001.

     Interest income of $339,554 in the three quarters of fiscal
2001 was $77,957 (30%) higher than in the three quarters of fiscal
2000.  The Company's average invested balance was approximately 17%
higher and its weighted average interest rate was approximately
0.57% per annum higher than for the three quarters of fiscal 2000.

     During the three quarters of fiscal 2000, the Company sold
available-for-sale securities and realized gains of $90,238, which
were included in other income.  There were no such sales in the
three quarters of fiscal 2001.

     Other expenses in the three quarters of fiscal 2001 were legal
expenses incurred in connection with a suit brought against CTT,
some of its subsidiaries and directors (See Note 6 to the
accompanying Consolidated Financial Statements).

     Forward-Looking Statements

     Statements about the Company's future expectations, including
development and regulatory plans, and all other statements in this
Quarterly Report on Form 10-Q other than historical facts, are
"forward-looking statements" within the meaning of applicable
Federal Securities Laws and are not guarantees of future
performance.  These statements involve risks and uncertainties
related to market acceptance of and competition for the Company's
licensed technologies and other risks and uncertainties inherent in
the Company's business, including those set forth in Item 1 of the
Company's Annual Report on Form 10-K for the year ended July 31,
2000, and other factors that may be described in the Company's
filings with the Securities and Exchange Commission, and are subject
to change at any time.  The Company's actual results could differ
materially from these forward-looking statements.  The Company
undertakes no obligation to update publicly any forward-looking
statement.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

                     PART II - OTHER INFORMATION


Item 2.   Changes in Securities and Use of Proceeds

     On February 26, 2001, the registrant issued to J. Scott Bechtel
2,564 shares of the registrant's common stock at $7.80 per share
(the average of the high and low prices on the American Stock
Exchange on February 26, 2001).  The shares were issued in
consideration for an agreed moving allowance.  No underwriters were
involved in this transaction.  The shares were exempt from
registration under Section 4(2) of the Securities Act of 1933 and
the certificate for these shares contained a restrictive legend.

Item 6.   Exhibits and Reports on Form 8-K               Page

A)   Exhibits

     11.1 Schedule of computation of earnings
          per share for the three and nine months
          ended April 30, 2001 and 2000.                   22

B)        Reports on Form 8-K

     No reports on Form 8-K were filed during the quarter for which
this report is filed.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.


                                    COMPETITIVE TECHNOLOGIES, INC.
                                    (Registrant)

Date:  June 14, 2001             By: s/ Frank R. McPike, Jr.
                                     Frank R. McPike, Jr.
                                     President,
                                     Chief Executive Officer,
                                     Chief Financial Officer
                                     and Authorized Signer